Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis
BackgroundAspirin use has been suggested to reduce the incidence of ovarian cancer (OC) in women. However, previous studies regarding the association between aspirin use and mortality in women with OC showed inconsistent results. We aimed to evaluate the association between aspirin use and mortality...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.575831/full |
id |
doaj-348a5ea361f14e5db6be5567b6cac7bd |
---|---|
record_format |
Article |
spelling |
doaj-348a5ea361f14e5db6be5567b6cac7bd2021-02-01T06:20:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-02-011010.3389/fonc.2020.575831575831Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-AnalysisXiaxia Man0Baogang Wang1Yuying Tan2Xiaolin Yang3Songling Zhang4Department of Oncological Gynecology, First Hospital, Jilin University, Changchun, ChinaDepartment of Cardiac Surgery, First Hospital, Jilin University, Changchun, ChinaDepartment of Echocardiography, First Hospital, Jilin University, Changchun, ChinaDepartment of Geriatrics, First Hospital, Jilin University, Changchun, ChinaDepartment of Oncological Gynecology, First Hospital, Jilin University, Changchun, ChinaBackgroundAspirin use has been suggested to reduce the incidence of ovarian cancer (OC) in women. However, previous studies regarding the association between aspirin use and mortality in women with OC showed inconsistent results. We aimed to evaluate the association between aspirin use and mortality in women with OC in a meta-analysis.MethodsRelevant cohort studies were obtained via search of PubMed, Cochrane’s Library, and Embase databases from inception to May 3, 2020. A random-effect model, which incorporates the potential heterogeneity among the included studies, was used to pool the results. Predefined stratified analyses were applied to evaluate the potential study characteristics on the outcome, including the timing of aspirin use, dose of aspirin, age of the women, and the clinical stages of the cancer. Sensitivity analysis by omitting one study at a time was used to assess the stability of the results.ResultsSix cohort studies including 17,981 women with OC were included. Pooled results showed that aspirin use had no statistically significant association with mortality in these patients (adjusted risk ratio [RR]: 0.85, 95% confidence interval [CI]: 0.70 to 1.02, p = 0.08; I2 = 69%). The results were similar for OC-specific mortality (RR: 0.85, 95% CI: 0.57 to 1.26, p = 0.41) and all-cause mortality (RR: 0.78, 95% CI: 0.55 to 1.11, p = 0.17). Stratified analyses suggested that aspirin use had no statistically significant association with mortality risk in OC regardless the timing of aspirin use, dose of aspirin, age of the women, or the clinical stages of the cancer. Funnel plots suggested potential risk of publication bias (p all > 0.05). However, further “trim-and-fill” analysis incorporating hypothesized unpolished studies to achieve symmetrical funnel plots showed similar results of the meta-analysis (RR: 0.91, 95% CI: 0.74 to 1.13, p = 0.39).ConclusionsCurrent evidence from observational studies indicated that aspirin use had no statistically significant association with mortality in women with OC.https://www.frontiersin.org/articles/10.3389/fonc.2020.575831/fullaspirinovarian carcinomamortalitycohort studiesmeta-analysis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xiaxia Man Baogang Wang Yuying Tan Xiaolin Yang Songling Zhang |
spellingShingle |
Xiaxia Man Baogang Wang Yuying Tan Xiaolin Yang Songling Zhang Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis Frontiers in Oncology aspirin ovarian carcinoma mortality cohort studies meta-analysis |
author_facet |
Xiaxia Man Baogang Wang Yuying Tan Xiaolin Yang Songling Zhang |
author_sort |
Xiaxia Man |
title |
Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis |
title_short |
Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis |
title_full |
Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis |
title_fullStr |
Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis |
title_full_unstemmed |
Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis |
title_sort |
aspirin use and mortality in women with ovarian cancer: a meta-analysis |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-02-01 |
description |
BackgroundAspirin use has been suggested to reduce the incidence of ovarian cancer (OC) in women. However, previous studies regarding the association between aspirin use and mortality in women with OC showed inconsistent results. We aimed to evaluate the association between aspirin use and mortality in women with OC in a meta-analysis.MethodsRelevant cohort studies were obtained via search of PubMed, Cochrane’s Library, and Embase databases from inception to May 3, 2020. A random-effect model, which incorporates the potential heterogeneity among the included studies, was used to pool the results. Predefined stratified analyses were applied to evaluate the potential study characteristics on the outcome, including the timing of aspirin use, dose of aspirin, age of the women, and the clinical stages of the cancer. Sensitivity analysis by omitting one study at a time was used to assess the stability of the results.ResultsSix cohort studies including 17,981 women with OC were included. Pooled results showed that aspirin use had no statistically significant association with mortality in these patients (adjusted risk ratio [RR]: 0.85, 95% confidence interval [CI]: 0.70 to 1.02, p = 0.08; I2 = 69%). The results were similar for OC-specific mortality (RR: 0.85, 95% CI: 0.57 to 1.26, p = 0.41) and all-cause mortality (RR: 0.78, 95% CI: 0.55 to 1.11, p = 0.17). Stratified analyses suggested that aspirin use had no statistically significant association with mortality risk in OC regardless the timing of aspirin use, dose of aspirin, age of the women, or the clinical stages of the cancer. Funnel plots suggested potential risk of publication bias (p all > 0.05). However, further “trim-and-fill” analysis incorporating hypothesized unpolished studies to achieve symmetrical funnel plots showed similar results of the meta-analysis (RR: 0.91, 95% CI: 0.74 to 1.13, p = 0.39).ConclusionsCurrent evidence from observational studies indicated that aspirin use had no statistically significant association with mortality in women with OC. |
topic |
aspirin ovarian carcinoma mortality cohort studies meta-analysis |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2020.575831/full |
work_keys_str_mv |
AT xiaxiaman aspirinuseandmortalityinwomenwithovariancancerametaanalysis AT baogangwang aspirinuseandmortalityinwomenwithovariancancerametaanalysis AT yuyingtan aspirinuseandmortalityinwomenwithovariancancerametaanalysis AT xiaolinyang aspirinuseandmortalityinwomenwithovariancancerametaanalysis AT songlingzhang aspirinuseandmortalityinwomenwithovariancancerametaanalysis |
_version_ |
1724315737514835968 |